Ice and fire heaven! MoonLake's drug trial data failure leads to stock price collapse, while competitor UCB rises sharply in response.

According to the information obtained by Wise Finance APP, the late-stage clinical trial data of an experimental skin disease drug announced by Swiss biotechnology company MoonLake Immunotherapeutics (MLTX.US) is below expectations. Due to this news, as of the time of publication, MoonLake's pre-market stock price in the US plummeted by over 86% on Monday, while its competitor Belgian pharmaceutical company UCB SA saw its stock price rise by 20% at one point. In addition, the stock price of Financiere de Tubize SA, the public investment tool of UCB founder Emmanuel Janssen's family, also soared significantly, rising by 17% at one point to reach a historic high.